Data Transparency and Rare Disease: Privacy versus Public Interest?
AUTORIA> Kanksha Mahadevia Ghimire; Trudo Lemmens
2021 · Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game? · Toronto · P. 184–218
Ler na fonte (página da editora) ↗DOI 10.3138/9781487529055-009
REFERÊNCIA
Formato COAL (Canadian Open Access Legal Citation Guide)
K.M. Ghimire & T. Lemmens, “Data Transparency and Rare Disease: Privacy versus Public Interest?” in K. Fierlbeck, J. Graham & M. Herder, eds, Transparency, Power, and Influence in the Pharmaceutical Industry (University of Toronto Press, 2021)
Formato RJAL (Guide canadien de la référence juridique en accès libre)
K.M. Ghimire et T. Lemmens, « Data Transparency and Rare Disease: Privacy versus Public Interest? » dans K. Fierlbeck, J. Graham et M. Herder, dir, Transparency, Power, and Influence in the Pharmaceutical Industry, University of Toronto Press, 2021